非小细胞肺癌获得性耐药和表皮生长因子受体靶向治疗耐受机制研究进展  

Research progress in mechanisms of acquired drug resistance and EGFR-targeted therapy tolerance in non-small cell lung cancer

作　　者：谢思华 高志超 张维 邢佳会 梁经纬[1,3] 孟繁浩 XIE Sihua;GAO Zhichao;ZHANG Wei;XING Jiahui;LIANG Jingwei;MENG Fanhao(School of Pharmacy/Key Laboratory of Research and Development of Small Molecule Targeted Antitumor Drugs,China Medical University,Shenyang Liaoning 110122,China;Department of Medical Oncology,Cancer Hospital&Institute,Shenyang Liaoning 110044,China;School of Pharmacy,Hainan Medical University,Key Laboratory of Research and Development of Tropical Medicinal Plants,Hainan Province,Haikou Hainan 571199,China)

机构地区：[1]中国医科大学药学院,小分子靶向抗肿瘤药物研究与开发重点实验室,辽宁沈阳110122 [2]辽宁省肿瘤医院肿瘤内科,辽宁沈阳110044 [3]海南医学院药学院,海南省热带药用植物研发重点实验室,海南海口571199

出　　处：《中国药物警戒》2024年第10期1081-1086,共6页Chinese Journal of Pharmacovigilance

基　　金：国家自然科学基金资助项目(82103998)。

摘　　要：目的探讨靶向表皮生长因子受体(EGFR)的特异性酪氨酸激酶抑制剂(EGFR-TKIs)在治疗该靶点突变的非小细胞肺癌(NSCLC)中的研究进展。方法重点讨论EGFR的靶向治疗方案,并详细阐述EGFR-TKIs的耐药机制,以及耐药持久性(DTP)细胞的特征和EGFR突变导致NSCLC耐药的机制基础。结果EGFR靶向治疗疗效显著,但会引起药物耐受或耐药细胞的出现,最终导致肿瘤复发。结论深入研究药物耐受性和获得性耐药的根本原因,有助于提高癌症治疗的效果。Objective To summarize the progress in treatment of non-small cell lung cancer(NSCLC)with mutations by specific tyrosine kinase inhibitors(EGFR-Tkis)that target the epidermal growth factor receptor(EGFR).Methods Targeted therapies with EGFR currently available were highlighted.The common mechanisms of EGFR-TKIs resistance were elaborated.The characteristics of drug-tolerant persister(DTP)cells and the mechanism of EGFR mutation leading to drug resistance in NSCLC were discussed.Results EGFR-targeted therapies could cause drug-resistance or drug-resistant cells,ultimately leading to tumor recurrence.Conclusion Insights into drug tolerance and underlying causes of resistance can help improve the effectiveness of cancer treatment.

关 键 词：非小细胞肺癌 表皮生长因子受体 靶向治疗 酪氨酸激酶抑制剂 药物耐受性 获得性耐药 

分 类 号：R979.1[医药卫生—药品]